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Mutations in the Fas Antigen in Patients With Multiple Myeloma
By Terry H. Landowski, Ning Qu, Ibrahim Buyuksal, Jeffrey S. Painter, and William S. Dalton
Programmed cell death, or apoptosis, is well documented as eloma. Using reverse transcriptase-polymerase chain reac-
a physiological means of eliminating activated lymphocytes tion (RT-PCR), single-stranded conformation polymorphism
and maintaining immune homeostasis. Apoptosis has also (SSCP) analysis, and DNA sequencing, we examined the
been implicated in the targeting of tumor cells by cytotoxic T cDNA structure of the Fas antigen in 54 bone marrow (BM)
lymphocytes and natural killer cells. One of the two primary specimens obtained from myeloma patients. Six patient
mechanisms used in cell-mediated cytotoxicity is the Fas/ specimens (11%) did not express detectable levels of Fas
FasLigand system. Activated or transformed cells expressing antigen mRNA. Of the 48 BM specimens which did express
the Fas antigen on their surface are susceptible to killing Fas antigen, 5 (10%) displayed point mutations. All of the
by immune effector cells that express the Fas ligand. Many mutations identiﬁed were located in the cytoplasmic region
neoplastic cells, including those derived from patients with of the Fas antigen known to be involved in transduction of
multiple myeloma, express Fas antigen on their surface, but an apoptotic signal. Two separate individuals demonstrated
do not undergo apoptosis in response to antigen crosslink- an identical mutation at a site previously shown to be mu-
ing. One possibility for the lack of Fas-mediated apoptosis tated in the congenital autoimmune syndrome, ALPS. One
includes mutations in the Fas antigen. Loss of function muta-
patient exhibited a point mutation at a site only two amino
tions in the Fas antigen have been associated with congeni-
acids removed from the documented lesion of the lpr
cg
tal autoimmune disease in humans, and have been deﬁned
mouse. Although the functional status of these point muta- as the genetic defect the in lpr mice. Mutations in the Fas
tions remains to be determined, we propose that Fas antigen antigen have not been previously described in cancer pa-
mutations may contribute to the pathogenesis and progres- tients. In this study, we show that mutations occur in the
sion of myeloma in some patients. Fas antigen which may cause loss of function and contribute
q 1997 by The American Society of Hematology. to the pathogenesis of the neoplastic disease, multiple my-
T
reactive lymphocytes during ontogeny, and activated lym-
phocytes following an immune response.
5,6 Aberrant expres-
HE FAS ANTIGEN (Apo-1/CD95) is a 45-kD trans-
membrane protein of the tumor necrosis factor receptor
(TNF-R) family which can induce programmed cell death sion or function of the Fas antigen has been associated with
both human and animal diseases, most particularly alter- when crosslinked by ligand or speciﬁc antibodies.
1,2 This
family of proteins is characterized by a cysteine-rich extra- ations that affect the signal transducing death domain. lpr
Mice represent a model of autoimmune disease characterized cellular domain, and a highly conserved cytoplasmic region
of 70 to 80 amino acids known as the death domain, which by lymphadenopathy, hypergammaglobulinemia, and auto-
immunity.
7,8 The genetic defect in lpr
cg mice has been identi- has been shown to be necessary and sufﬁcient for transduc-
tion of an apoptotic signal.
3 Crosslinking by Fas ligand or ﬁed as a point mutation within the death domain of the Fas
antigen which completely abolishes the apoptotic response agonistic antibody induces the association of the Fas death
domain with cytoplasmic proteins, forming a death-inducing of lpr cells. lpr Mice fail to eliminate reactive T cells, re-
sulting in the accumulation of CD4
0CD8
0 T cells and the signaling complex (DISC).
4 Site-directed mutagenesis stud-
production of autoantibodies with a Lupus-like syndrome. ies of the Fas antigen have shown that deletion of the 15
Similar syndromes have been identiﬁed in humans and carboxy-terminal amino acids enhance the response to Fas
associated with Fas antigen mutations. Several recently pub- antibody-mediated cell death, indicating a negative regula-
lished studies have identiﬁed function ablating mutations in tory role for this region, while deletions or mutations further
patients with a congenital autoimmune lymphoproliferative into the death domain abrogate DISC formation and prevent
syndrome (ALPS).
9-12 This disease is identical to the lpr apoptosis.
3,4
phenotype in the accumulation of activated lymphocytes re- The Fas/Fas ligand system of apoptosis plays a central
sulting in lymphadenopathy, hypergammaglobulinemia, and role in the regulation of hemostasis by elimination of self-
autoimmune cytopenias. Peripheral blood mononuclear cells
(PBMCs) isolated from ALPS patients show a diminished
apoptotic response to crosslinking by anti-Fas monoclonal From the H. Lee Mofﬁtt Cancer Center and Research Institute,
antibodies (MoAbs). The proﬁle of ALPS patients is identi- University of South Florida, Tampa; and the Arizona Cancer Center,
University of Arizona, Tucson. cal to an autoimmune disorder known as Canale-Smith syn-
Supported in part by the Molecular Biology Core Facility at H. drome, which was also associated with heterozygous muta-
Lee Mofﬁtt Cancer Center and Research Institute. tions in the Fas antigen.
13 In each of these disorders, Fas
Submitted June 17, 1997; accepted August 26, 1997. mutations have been identiﬁed in the signal-transducing
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Mofﬁtt Cancer Center, University of South Florida, 12902 Magnolia To date, diseases associated with mutations in either the
Dr, Tampa, FL 33612. Fas antigen or Fas ligand have primarily been congenital The publication costs of this article were defrayed in part by page
autoimmune disorders; however, no mutations have been charge payment. This article must therefore be hereby marked
described in cancer patients. Multiple myeloma is a neoplas- ‘‘advertisement’’ in accordance with 18 U.S.C. section 1734 solely to
tic disease of plasma cells characterized by a latent accumu- indicate this fact.
lation of monoclonal cells, which typically display low pro- q 1997 by The American Society of Hematology.
0006-4971/97/9011-0044$3.00/0 liferative activity. Several lines of evidence indicate that,
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Fig 1. Diagrammatic representation of the Fas an-
tigen cDNA. Arrows indicate positions of primers
used for RT-PCR. Hatched boxes represent cysteine-
rich extracellular region. Solid box represents the
transmembrane region, and the dark hatched box
respresents the death domain.
were optimized for strand separation and detection of a single base although the original genetic insult occurs in the pre-B or
change.
21-24 Fragments were analyzed under three electrophoretic early B-cell population, lymphocyte development occurs
conditions: (1) 5% to 6% acrylamide with 1% to 5% crosslinking along normal lines before antigenic stimulation.
14,15 Thus, it
at 47C, (2) 6% acrylamide with 10% glycerol at room temperature, is likely that the transforming event is not a loss of growth
and (3) the FMC Mutation Detection Enhancement (MDE) system control, but rather, a loss of death control. Previously pub-
(Intermountain Scientiﬁc, Kaysville, UT). cDNAs showing mobility
lished studies showed that although many myeloma cells shifts were extracted from the gel, and re-ampliﬁed for 42 cycles
express Fas antigen on their cell surface, only some respond using the same primer set, inserted into the TA cloning vector
to an apoptotic signal when treated with the apoptosis induc- pCR2.1 (Invitrogen, La Jolla, CA), and sequenced either by Seque-
ing anti-Fas antibody.
16-18 We have examined the expression nase 2.0 (USB, Cleveland, OH) or ALF (Pharmacia, Piscataway,
NJ). To control for potential PCR error, all patient samples dis- of the Fas antigen in bone marrow (BM) specimens obtained
playing mobility shifts were analyzed by two independent PCR reac- from 54 multiple myeloma patients to determine if mutations
tions. Three to ﬁve clones were selected for sequencing, and conﬁr- occur in the Fas antigen. If present, these mutations may
mation of point mutations was performed with both forward and contribute to the pathogenesis or progression of myeloma.
reverse primers T7 and SP6 or M13. Fragment analysis and align- Using reverse transcriptase-polymerase chain reaction
ment was done using the programs Mac Vector and AssemblyLign (RT-PCR) and single-stranded conformation polymorphism
(Oxford Molecular Group, Campbell, CA).
(SSCP) analysis, we have identiﬁed point mutations resulting
in a single amino acid change in the Fas antigen of myeloma
RESULTS patients. Although the functional signiﬁcance of these muta-
tions remains to be deﬁned, all mutations occur in the death Because programmed cell death through the Fas/Fas li-
domain where they are likely to effect the signal transducing gand system has been implicated in the elimination of acti-
capacity of the protein. vated B cells both during ontogeny and in immune physiol-
ogy, we examined the Fas antigen in myeloma tumor cells
MATERIALS AND METHODS for mutations which could contribute to a failure of immune
Patient population. BM specimens were obtained during routine surveillance in the progression of disease. The cDNA se-
clinical assessment of multiple myeloma patients. PB lymphocytes quence of the Fas antigen was divided into three amplicons
(PBLs) were obtained from normal volunteers. BM mononuclear of 316 (Fas I), 330 (Fas II), and 392 bp (Fas III), spanning
cells were isolated on a Ficoll gradient and cryopreserved in RPMI the entire coding region
19 (Fig 1). Because myeloma patient
with 20% fetal bovine serum (FBS; Gemini, Calabasas, CA) and
BM samples typically display tumor cell content from 2% 10% dimethyl sulfoxide (DMSO) for up to 4 years before RNA
to 98%, control experiments were performed to determine extraction and analysis. Cultured cell lines used for control experi-
the minimum percentage of cells with a single base change ments were the human myeloma cell line 8226 and the human T-
which could be detected in our SSCP system.
25 For these cell leukemia cell line, both originally obtained from American Type
Culture Collection (ATCC; Rockville, MD). All cell culture reagents experiments we took advantage of a previously identiﬁed
were from Sigma (St Louis MO) unless otherwise noted. polymorphism at bp 836.
19 Sequence analysis showed that
RT-PCR and SSCP analysis. Total RNA was isolated by lysis the T-cell leukemia cell line, CEM, expressed the alternative
in guanidine isothiocyanate followed by cesium chloride density codon ACT, while the myeloma cell line 8226 contained the
centrifugation and ethanol precipitation. Fifty to 100 ng of RNA was higher frequency codon, ACC. CEM cells were mixed with
reverse transcribed by random hexamer priming, and the indicated 8226 cells at ratios of 1:1, 1:5, 1:10, 1:20, and 1:50. Total
fragments ampliﬁed by 35 cycles in a 9600 Perkin Elmer Thermocy-
RNA was isolated from the mixed cell population, and the cler (Foster City, CA). Primers, shown in Figure 1 (Biosynthesis,
RT-PCR products analyzed by SSCP. With this system, we Lewisville, TX), ampliﬁed products corresponding to bp 195-525,
were able to identify mobility shifts with as little as 5% bp 520-863, and bp 813-1202, which covered the entire open reading
heterogeneous mRNA (data not shown). Using this criteria, frame of the Fas antigen.
19 Radioisotope was incoporated into the
PCR products for detection by autoradiogram. PCR conditions used 54 myeloma patient BM samples displaying a minimum of
for Fas II and Fas III ampliﬁcation were: 60 seconds at 947C; dena- 5% plasma cells on histopathology were selected for analy-
ture 15 seconds at 947C; anneal 15 seconds at 527C; extend 15 sis. SSCP conditions for strand separation were further opti-
seconds at 727C; ﬁnal extension 60 seconds at 727C. Due to the high mized using a PCR product which introduced a single base
GC content of the Fas I amplicon, the denaturation step was in- change in the upstream primer (data not shown.)
creased to 3 minutes, and Mg
2/ concentraction in the PCR buffer Of the 54 BM specimens analyzed, 48 expressed Fas anti-
was increased to 2.5 mmol/L for optimum ampliﬁcation. Identity of
gen mRNA at levels detectable by RT-PCR. In the 6 patients the products was established by restriction digest and direct sequenc-
who did not express Fas antigen mRNA, the integrity of the ing. A 215-bp fragment of Histone 3.3 was ampliﬁed as a control for
mRNA was conﬁrmed by ampliﬁcation of the housekeeping RNA integrity.
20 After ampliﬁcation, PCR products were denatured 5
gene Histone 3.3. SSCP analysis identiﬁed mobility shifts minutes at 807C at a 1:10 dilution of sample buffer containing 98%
formamide/5 mmol/L NaOH. SSCP gel conditions for each amplicon in the Fas III amplicon in 15 of the 48 patient specimens
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Fig 2. RT-PCR SSCP analysis of the Fas antigen in myeloma pa-
tient BM specimens.
32P-labeled PCR products are separated on a 6%
acrylamide (49.5:0.5 bis) gel. Lane 1, PBLs; lane 2, 8226; lane 3,
BAKA27 (normal); lane 4, FOSM32. Arrow indicates band excised for
sequence analysis.
Fig 3. Sequence analysis of FasIII RT-PCR products extracted from
(Fig 2). These bands were always seen in addition to the SSCP gels. Sequence shown is bp 966 to 1011, including the point
mutation G to T at bp 999 in patient FOSM32. The normal PB se- wild-type cDNA. Because whole mononuclear cell prepara-
quence is shown on the left (PBL). tions were used for analysis, we are unable to distinguish
homozygous versus heterozygous mutations in the myeloma
cells. The Fas III fragment encompasses the cytoplasmic
region, including the signal transducing death domain. were found to be heterozygous for the previously described
Shifted bands were extracted from the SSCP gel, re-ampli- polymorphism at bp 836.
19
ﬁed by PCR, and ligated into the pCR2.1 cloning vector for Analysis of the Fas II amplicon, which encompasses the
bidirectional sequencing. transmembrane domain, showed the expression of alternative
Sequence analysis showed point mutations in the Fas anti- splice products in nearly all patient specimens, as has been
gen cytoplasmic domain of 7 myeloma patients (Table 1). previously described.
26,27 Extraction and sequence analysis
Two of these patients, FOSM32 and NYSR35, showed an of the lower molecular weight amplicon identiﬁed a deletion
identical G to T transversion at bp 999 (Fig 3). Translation of 73 bp corresponding to exon 6. In the majority of these
of the open reading frame of the Fas antigen indicated this patients, expression of the truncated mRNA appeared equiv-
mutation would result in the substitution of ASP to TYR at alent to that of the full-length mRNA. These protein products
amino acid 253.AGt oTtransversion in patient BRYR24 are predicted to be secreted as soluble factors due to the
was identiﬁed at bp 1066, resulting in the substitution of absence of a transmembrane domain, and have been identi-
TYR to SER of amino acid 275. Patient SUTH23 showed ﬁed in normal subjects as well as patients with autoimmune
an A to G transition at bp 946, resulting in LYS to ARG at disease such as systemic lupus erythematosis. In vitro studies
235. Although this is a conservative substitution, it is only have shown an inhibitory effect of Fas antigen crosslinking
two amino acids away from the ILE to ASN mutation at by the transmembrane-deleted soluble factors; however, their
residue 238 in lpr
cg mice which completely abolishes the clinical signiﬁcance has not been established.
signal transduction activity of the Fas antigen. Patient Only 1 of the 48 patient specimens that were positive for
WEBW41 was found to have an A to C transversion at bp Fas antigen expression showed a mobility shift on SSCP
1032, which resulted in ASN to HIS change at amino acid analysis of the Fas II domain. Sequence analysis revealed a
264. Two patient specimens, CLAA48 and CONH24, were C to T transversion that did not affect the amino acid se-
found to have silent mutations effecting no change in the quence. No mutations were detected in the extracellular re-
amino acid sequence. The remaining 8 patient specimens gion designated Fas I; however, minor products representing
which demonstrated mobility shifts in the Fas III amplicon previously reported alternative splice variants were seen in
6 of 48 patients.
27,28 The signiﬁcance of these variants is not
yet known.
Table 1. Summary of Fas Antigen Mutations Identiﬁed
in Myeloma Patient BM Specimens DISCUSSION
Patient cDNA Sequence Change Amino Acid Change Multiple myeloma is a neoplastic disease of plasma cells
characterized by the latent accumulation of monoclonal BRYR24 G to T bp 1066 275 Tyr to Ser
CLAA48 C to T bp 1103 No change plasma cells which typically display a low proliferative in-
CONH24 T to C bp 941 No change dex. The disease progression of myeloma is characterized
FOSM32 G to T bp 999 253 Asp to Tyr by (1) cell proliferation, often regulated by autocrine growth
NYSR35 G to T bp 999 253 Asp to Tyr factors; (2) dissemination and vascular circulation of plasma
SUTH23 A to G bp 946 235 Lys to Arg cells; and (3) loss of programmed cell death leading to the
WEBW41 A to C bp 1032 264 Asn to His accumulation of tumor cells.
29,30 Programmed cell death me-
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diated by the Fas/Fas ligand system is one of two primary Several recent reports have provided evidence that
mechanisms used in the elimination of activated lympho- apoptosis induced by anticancer drugs share a common path-
cytes and maintainance of homeostasis. It has also been im- way with physiological mechanisms of cell death including
plicated in cell-mediated cytotoxicity of tumor cells by cyto- the Fas/Fas ligand system.
37-38 We have recently reported
toxic T lymphocytes and natural killer (NK) cells.
31,32 Loss that cell lines which are selected for resistance to chemother-
of function of the Fas antigen may contribute to the patho- apeutic agents are also resistant to Fas-mediated apoptosis.
18
genesis and progression of neoplasias by allowing suscepti- Conversely, Friesen et al
39 reported that cell lines selected
ble cells to evade immune surveillance. The prolonged sur- for resistance to Fas-mediated apoptosis are also resistant to
vival would allow the cell to accumulate mutations leading chemotherapeutic agents. These data suggest that aberrant
to malignancy.
6 function of the Fas antigen may contribute to enhanced sur-
Several recent reports have identiﬁed Fas antigen expres- vival of tumors under treatment with chemotherapeutic
sion on primary myeloma cells as well as cultured myeloma agents, and promote the emergence of drug-resistant disease.
cell lines.
33-35 However, not all myeloma cells are capable Further deﬁnition of the mechanisms involved in apoptosis
of undergoing apoptosis in response to crosslinking with may contribute to the development of more effective thera-
anti-Fas antibody.
16-18 We have examined the Fas antigen peutic strategies.
cDNA in BM samples obtained from 54 patients with multi- Genetic defects in the ability of a cell to undergo apoptosis
ple myeloma, and have identiﬁed mutations in the signal has deﬁned a new class of proto-oncogenes, those which
transducing region of the Fas antigen that may account for effect cell death rather than cell proliferation.
6,40,41 Although
the functional deﬁciencies identiﬁed in those studies. Fas antigen has been proposed as a tumor-suppressor gene,
Loss of function of the Fas antigen is associated with this study is the ﬁrst to show mutations in the coding se-
hyperplasia and lymphoproliferation. A congenital autoim- quence of Fas associated with human neoplasia. We propose
mune disorder known as autoimmune lymphoproliferative that Fas antigen mutations may contribute to the pathogene-
syndrome (ALPS) has been attributed to Fas antigen muta- sis and progression of some hematologic malignancies. In
tions. In three separate studies, function ablating mutations this study, we report point mutations effecting the signal
in the fas antigen were identiﬁed in patients with ALPS.
9-11
transduction domain of the Fas antigen in 10% of patients
This disease is similar to the phenotype of the lpr mouse analyzed. Two unrelated patients showed an identical point
which is characterized by an accumulation of activated lym- mutation, located immediately adjacent to a 2-bp deletion
phocytes resulting in lymphadenopathy, hypergammaglobu- which displays a dominant negative effect of Fas function
linemia, and autoimmune cytopenias. PBMCs isolated from in ALPS patients. None of the mutations we identiﬁed have
ALPS patients show a diminished apoptotic response to been reported to occur in normal tissues.
10,13,19 Functional
crosslinking by anti-Fas MoAbs. Molecular analysis of the analysis of the mutations is currently underway in our labora-
Fas antigen in these patients showed unique mutations. Five tory.
of the 11 combined patients analyzed in these studies demon-
strated mutations within exon 9 of the Fas antigen. In the
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